Boehringer Ingelheim has appointed Lykke Hinsch Gylvin as Head of Medicine and Chief Medical Officer, effective November 1, 2022.
Most recently, Gylvin served as Vice President, Global Medical Franchise Head, Neuroscience at Novartis. She brings more than 20 years of pharmaceutical experience, ranging from early-stage drug development to post-approval lifecycle management.
During her career, Gylvin has held several global and regional senior leadership roles at companies such as AstraZeneca, Roche, and recently Novartis.
